AN2 Therapeutics Reports Q2 Earnings, Exceeds Expectations

AN2 Therapeutics reported Q2 EPS of 21 cents, beating last year's loss of 48 cents. The company highlighted momentum in its boron chemistry pipeline, including progress in Chagas disease and melioidosis programs, as well as preclinical data for NTM treatment epetraborole. AN2 is exploring plans to initiate a proof-of-concept trial for M. abscessus.

AN2 Therapeutics (ANTX) reported its Q2 earnings per share (EPS) of 21 cents, surpassing last year's loss of 48 cents. The company highlighted continued momentum in its boron chemistry pipeline, with progress in its Chagas disease and melioidosis programs, and preclinical data for NTM treatment epetraborole. AN2 is exploring plans to initiate a proof-of-concept trial for M. abscessus.

The company's Q2 GAAP EPS of -$0.21 beat by $0.13, reflecting a significant improvement over last year's performance. Eric Easom, Co-Founder, Chairman, President, and CEO of AN2 Therapeutics, commented on the company's progress, noting that "We saw continued momentum this quarter across our boron chemistry pipeline as we look to develop high-impact drugs that address serious and overlooked conditions" [1].

In the Chagas disease program, AN2 recently dosed the first Phase 1 cohort and announced a collaboration with the Drugs for Neglected Diseases initiative (DNDi). This collaboration will rapidly advance preparations for the Phase 2 study and allow AN2 to maintain critical investments in other programs. The company expects to complete Phase 1 dosing by the end of 2025 [3].

Preclinical studies in nonhuman primates naturally infected with T. cruzi have shown AN2-502998's curative potential in chronic Chagas disease. AN2 is committed to making a change for the community of patients suffering from chronic Chagas disease, which affects an estimated 6-7 million people worldwide, including approximately 300,000 people in the U.S. and over 100,000 in Europe [3].

In melioidosis, observational data shared this quarter underscored the acute lethality of this potential biothreat, emphasizing its potential danger to homeland security and to U.S. troops serving abroad. AN2 is actively exploring plans to initiate a proof-of-concept trial in M. abscessus and will provide an update in the coming months [1].

AN2's cash runway is anticipated to fund operations into 2028, with cash, cash equivalents, and investments of $71.2 million at June 30, 2025 [2].

References:
[1] https://www.tipranks.com/news/the-fly/an2-therapeutics-reports-q2-eps-21c-vs-48c-last-year-thefly
[2] https://seekingalpha.com/news/4484210-an2-therapeutics-gaap-eps-of-0_21-beats-by-0_13
[3] https://www.businesswire.com/news/home/20250812650698/en/AN2-Therapeutics-Commences-First-in-Human-Clinical-Trial-of-Oral-AN2-502998-for-Chagas-Disease
[4] https://www.biospace.com/press-releases/an2-therapeutics-commences-first-in-human-clinical-trial-of-oral-an2-502998-for-chagas-disease